The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma— continues to rise; however, treatment options remain limited. Targeted therapies, including Herceptin (Roche / Genentech / Chugai [for HER2-positive patients only]) and Cyramza (Eli Lilly), have been approved exclusively for gastric and GEJ adenocarcinoma patients across the major markets. Additional agents are also approved for later-line treatments in certain geographies, such as Keytruda (Merck & Co.), Opdivo (Bristol-Myers Squibb), and Lonsurf (Taiho). A plethora of agents including immunotherapies, vaccines, and a variety of targeted therapies are vying for approval in underserved patient segments, such as resectable disease or the first-line metastatic setting.
Geographies: United States, EU5, Japan.
Primary research: 20 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed and recurrent incidence of gastroesophageal cancer by country, segmented by HER2 status, histology, stage I-IV, and line of therapy.
Forecast: 10-year, annualized, drug-level sales and patient share of key gastroesophageal cancer therapies through 2028, segmented by brands / generics and market-relevant drug treatable populations.
Emerging therapies: Phase III: 12 drugs; Phase I / II: ~30 drugs.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.